← Back to Screener
Gyre Therapeutics, Inc. Common Stock (GYRE)
Price$7.94
Favorite Metrics
Price vs S&P 500 (26W)-12.25%
Price vs S&P 500 (4W)4.65%
Market Capitalization$725.03M
P/E Ratio (Annual)144.23x
All Metrics
P/CF (Annual)717.85x
Book Value / Share (Quarterly)$1.16
P/TBV (Annual)6.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)428.46%
Cash Flow / Share (Quarterly)$-0.01
Price vs S&P 500 (YTD)8.53%
Gross Margin (TTM)95.35%
Net Profit Margin (TTM)4.31%
EPS (TTM)$0.05
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$0.05
Revenue Growth (5Y)40.96%
EPS (Annual)$0.05
ROI (Annual)4.74%
Gross Margin (Annual)95.35%
Net Profit Margin (5Y Avg)-461.44%
Cash / Share (Quarterly)$0.57
P/E Basic Excl Extra (TTM)144.23x
Revenue Growth QoQ (YoY)33.45%
P/E Normalized (Annual)144.23x
ROA (Last FY)3.03%
Revenue Growth TTM (YoY)10.24%
EBITD / Share (TTM)$0.15
ROE (5Y Avg)-90.40%
Operating Margin (TTM)9.85%
Cash Flow / Share (Annual)$-0.01
P/B Ratio6.84x
P/B Ratio (Quarterly)6.05x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.90x
Net Interest Coverage (TTM)-14.38x
ROA (TTM)3.31%
EPS Growth QoQ (YoY)215.45%
EV / EBITDA (TTM)45.35x
EPS Incl Extra (Annual)$0.05
Current Ratio (Annual)5.60x
Quick Ratio (Quarterly)4.97x
3-Month Avg Trading Volume0.10M
52-Week Price Return-10.59%
P/E Incl Extra (TTM)144.23x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.09
P/S Ratio (Annual)6.22x
Asset Turnover (Annual)0.70x
52-Week High$11.78
Operating Margin (5Y Avg)-459.73%
EPS Excl Extra (Annual)$0.05
CapEx CAGR (5Y)45.00%
Tangible BV CAGR (5Y)-17.70%
26-Week Price Return-5.36%
Quick Ratio (Annual)4.97x
13-Week Price Return3.12%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.60x
Enterprise Value$687.963
Revenue / Share Growth (5Y)-41.41%
Asset Turnover (TTM)0.77x
Book Value / Share Growth (5Y)-42.88%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.66x
Pretax Margin (Annual)12.38%
Cash / Share (Annual)$0.57
3-Month Return Std Dev51.16%
Gross Margin (5Y Avg)57.41%
Net Income / Employee (TTM)$0
ROE (Last FY)4.74%
EPS Basic Excl Extra (Annual)$0.05
P/FCF (TTM)124.96x
Receivables Turnover (TTM)4.60x
EV / Free Cash Flow (TTM)444.83x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.05
Receivables Turnover (Annual)4.60x
ROI (TTM)5.46%
P/S Ratio (TTM)6.22x
Pretax Margin (5Y Avg)-446.04%
Revenue / Share (Annual)$1.13
Tangible BV / Share (Annual)$1.09
Forward P/E195.13x
Price vs S&P 500 (52W)-45.22%
P/E Ratio (TTM)144.23x
EPS Growth TTM (YoY)-60.17%
Year-to-Date Return12.46%
5-Day Price Return1.28%
EPS Normalized (Annual)$0.05
ROA (5Y Avg)-50.79%
Net Profit Margin (Annual)4.31%
Month-to-Date Return13.92%
Cash Flow / Share (TTM)$-18.23
EBITD / Share (Annual)$0.15
Operating Margin (Annual)9.85%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)717.85x
ROI (5Y Avg)-90.40%
P/E Excl Extra (TTM)144.23x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.05
P/TBV (Quarterly)6.42x
P/B Ratio (Annual)6.05x
Inventory Turnover (TTM)0.66x
Pretax Margin (TTM)12.38%
Book Value / Share (Annual)$1.16
Price vs S&P 500 (13W)0.74%
Beta2.57x
P/FCF (Annual)41.89x
Revenue / Share (TTM)$1.28
ROE (TTM)5.46%
52-Week Low$6.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GYREGyre Therapeutics, Inc. Common Stock | 6.22x | 10.24% | 95.35% | — | $7.94 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Gyre Therapeutics is a commercial-stage biopharmaceutical company specializing in small-molecule anti-inflammatory and anti-fibrotic therapies for organ fibrosis. The company commercializes ETUARY, Avatrombopag, and Nintedanib, while advancing Hydronidone (F351) for metabolic dysfunction-associated steatohepatitis liver fibrosis and a pipeline of earlier-stage candidates in China. Primary revenue derives from ETUARY and generic pharmaceutical sales in mainland China.